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INTRODUCTION
Adolescents are unique in that they are affected by different 
types of cancers, compared with other age groups, owing to hor-
monal and physical changes that influence cancer develop-
ment and responses to treatment.1,2 In the United States and Eu-
rope, more patients are diagnosed with invasive cancer during 
their second 15 years of life than their first 15 years.1,3,4 Cancer 
has unique characteristics in adolescents, and the distributions 
of cancer types change dramatically from adolescents to adult 
age groups.3
Because of the special needs of adolescents, their treatment 
is now considered a separate category in oncology. They appear 
to survive leukemia at better rates when treated using proto-
cols designed for children.5 However, their overall cancer sur-
vival rates have not appreciably improved in decades, and fur-
ther research is needed to improve treatment outcomes. The 
incidence of cancer has increased in adolescents and young 
adults, who are less likely to receive optimal medical and psy-
chosocial services for various reasons, including limited in-
surance coverage, delayed diagnosis, lower rates of participa-
tion in clinical trials, insufficient psychosocial/supportive care 
and follow-up care, and limited cancer prevention and early 
detection.6 Ignorance of the possibility of having cancer and 
receiving treatment more appropriate for adults also contribute 
to unimproved survival rates.3 The reasons for lack of adequate 
care in this patient population are thought to vary widely from 
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country to country; however, this topic requires further study.
Adolescents undergo more dynamic changes in physical and 
psychosocial development than young adults. During adoles-
cence, numerous unique hormonal, physical, and especially 
psychological changes occur,7 and psychosocial factors are of-
ten responsible for delayed cancer diagnosis.8-10 Adolescents 
can make many of their own decisions and have achieved some 
independence from their parents, but insufficient experience 
and information can lead to delays in seeking medical help.8-10 
Although some previous studies have associated diagnostic de-
lays with decreased survival, others have not.11-13 To improve 
cancer survival rates in adolescents, it is important to better un-
derstand the effect of delayed diagnosis on treatment results.
MATERIALS AND METHODS
Study population
Between January 1, 2000 and December 31, 2007, 914 patients 
aged 0–18 years of age were diagnosed with cancer and treat-
ed at Yonsei Cancer Center, Yonsei University Health System, 
Seoul, Korea. Of these patients, we included 592 patients with 
the seven most common cancers: acute lymphoid leukemia 
(ALL), acute myeloid leukemia (AML), non-Hodgkin lympho-
ma (NHL), central nervous system (CNS) tumors, sarcomas, 
neuroblastomas (NBs), and Wilms tumor (WT). To minimize 
heterogeneity in diagnoses of study cohort, we excluded Hodg-
kin lymphoma, extracranial germ cell tumors, hepatoblasto-
mas, Langerhans cell histiocytosis, and other cancers that had 
less than 30 patients. CNS tumors included medulloblastomas, 
primitive neuroectodermal tumors, pineoblastomas, germ cell 
tumors, and astrocytomas and excluded ependymomas and 
other less frequent tumors. Medical records showed symptom 
intervals (SIs) for all 592 patients, but patient delay (PD) for 
only 322 (54.4%) patients.
Patients were classified into two groups according to age: ad-
olescents (≥10 years), and children (<10 years). Ten years was 
chosen as the cut-off because it is the median age of pubertal 
development.14 We defined SI as the number of days between 
the first symptoms/signs of disease and date of diagnosis, PD 
as the number of days between the first symptoms/signs of dis-
ease and the date medical help was first sought, and “physician 
delay (PhyD)” as the number of days between the date medical 
help was first sought and date of diagnosis (Fig. 1). We defined 
SI >21 days as a long SI, and SI ≤21 days as a short SI. We calcu-
lated patient delay proportion (PDP) as PD divided by SI. If the 
PDP is over 0.5, it means that PD is composed of higher propor-
tion than PhyD in SI. The PDP cut-off point was 0.6. SI and PDP 
cut-off points were set using the Contal and O’Quigley meth-
od.15 Patients were ultimately classified into one of three groups: 
short SI, long SI/PDP <0.6, or long SI/PDP ≥0.6.
We also categorized all tumors as low-risk (LR) or high-risk 
(HR). For leukemia, we used the National Cancer Institute risk 
group classification, with Philadelphia chromosome-positive 
ALL, infantile leukemia, and AML with HR karyotypic features 
classified as HR. Stage 1 and 2 lymphomas were defined as LR, 
and higher stages of lymphomas as HR. For CNS tumors, grades 
1 and 2 (according the World Health Organization classifica-
tion) were defined as LR, and grades 3 or 4 as HR. For NBs, WTs, 
and bone and soft tissue sarcomas, we classified non-metastat-
ic disease as LR and metastatic disease as HR.
Statistical analysis
Overall survival (OS) was calculated as the time from the date 
of diagnosis to death due to any cause (before December 31, 
2012). Categorical variables were analyzed using the chi-square 
test. Continuous variables were analyzed using the Mann-Whit-
ney U test or Kruskal-Wallis test for non-parametric variables 
and Student t-test or analysis of variance for parametric vari-
ables. Survival was analyzed using the Kaplan-Meier method 
Table 1. Demographic Characteristics of Adolescents and Children
Characteristic
Age at diagnosis
Adolescents
(≥10 yrs), n=249
Children
(<10 yrs), n=343
Sex (p=0.267)
Female 104 (41.8%)* 159 (46.4%)
Male 145 (58.2%) 184 (53.6%)
Diagnosis (p<0.001†); diagnosis by risk (p<0.001 in ALL‡)
ALL (n=127) LR 0 (0%) 41 (100%)
HR 31 (36.0%) 55 (64.0%)
AML (n=36) LR 5 (55.6%) 4 (44.4%)
HR 14 (51.9%) 13 (48.1%)
NHL (n=59) LR 11 (52.4%) 10 (47.6%)
HR 14 (36.8%) 24 (63.2%)
CNS tumor (n=232) LR 41 (48.2%) 44 (51.8%)
HR 75 (51.0%) 72 (49.0%)
Abdomen (n=52) LR 1 (4.0%) 24 (96.0%)
HR 1 (4.0%) 26 (96.0%)
Sarcoma (n=86) LR 33 (64.7%) 18 (35.3%)
HR 23 (65.7%) 12 (34.3%)
ALL, acute lymphoblastic leukemia; LR, low risk; HR, high risk; AML, acute my-
eloid leukemia; NHL, non-Hodgkin lymphoma; CNS, central nervous system.
*Percentage is based on the total numbers in each group, †Distribution of 
specific diagnoses between children and adolescents group was significantly 
different (p<0.001), ‡Proportion of ALL by risk between children and adoles-
cents group was significantly different (p<0.001). p value of a t-test.Fig. 1. Symptom interval, patient delay, and physician delay.
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and compared using the log-rank test. Multivariate data anal-
ysis was carried out using linear regression and Cox propor-
tional hazard regression. Statistical significance in multivariate 
Cox models was determined using Wald test. Statistical analysis 
was performed using SAS version 9.2 software (SAS Institute, 
Cary, NC, USA).
RESULTS
Patient demographic characteristics
Of the 592 patients analyzed, the mean age at diagnosis was 
8.6±5.2 years. Two hundred forty-nine patients received a can-
cer diagnosis at or after 10 years of age (adolescents), and 343 
patients received a cancer diagnosis before 10 years of age (chil-
dren) (Table 1). In both groups, CNS tumors were the most com-
mon cancers. The second most common diagnosis was ALL 
in children and sarcoma in adolescents. The diagnosis pattern 
differed between the two groups (p<0.001) (Table 1). ALL was 
the only cancer type with a statistically significant difference 
in risk (LR vs. HR) between adolescents and children (p<0.001) 
(Table 1).
Survival data
The 5-year OS rate for all patients was 71.9±1.9% (Supplemen-
tary Fig. 1A, only online). The 5-year OS rates did not differ 
significantly between adolescents (71.4±2.9%) and children 
(72.3±2.4%; p=0.874). Patients with NHL had the highest 5-year 
OS rates (78.0±5.4%), whereas those with AML had the lowest 
(55.6±8.3%). Five-year OS rates were significantly lower in pa-
tients with HR tumors (60.9±2.6%) than LR tumors (88.8±2.1%; 
p<0.001). They were significantly higher in all patients with 
long SIs (76.9±2.3%) than in those with short SIs (65.6±2.9%; 
p=0.001) and in children with long SIs (79.0± 3.2%) than short 
SIs (66.3±3.5%; p=0.002) (Supplementary Fig. 1B, only online). 
They were also higher in adolescents with long SIs (74.8±3.4%) 
than short SIs (64.2±5.3%), but this difference was not signifi-
cant (p=0.141).
Table 2. Symptom Intervals of Adolescents and Children According to Cancer Diagnosis
Diagnosis
Age at diagnosis
p value†All group Adolescents Children
n SI* n SI n SI
ALL
Total 127 14 (0–332) 31 14 (2–332) 96 14 (0–188) 0.494
LR 41 14 (1–188) 0 - 41 14 (1–188) -
HR 86 14 (0–332) 31 14 (2–332) 55 13 (0–97) 0.273
AML
Total 36 11 (0–84) 19 10 (0–82) 17 21 (3–84) 0.208
LR 9 21 (3–29) 5 13 (3–29) 4 21 (7–28) 0.730
HR 27 9 (0–84) 14 8 (0–82) 13 9 (3–84) 0.280
NHL
Total 59 23 (0–1260) 25 28 (0–1260) 34 22 (2–365) 0.124
LR 21 28 (0–1260) 11 42 (0–1260) 10 21 (10–365) 0.152
HR 38 21 (2–146) 14 28 (2–146) 24 21 (2–85) 0.463
CNS tumor
Total 232 28 (0–2034) 116 29 (0–1079) 116 25 (0–2034) 0.007
LR 85 31 (0–1079) 41 31 (0–1079) 44 28 (0–371) 0.320
HR 147 28 (0–2034) 75 28 (0–635) 72 21 (0–2034) 0.006
Abdomen
Total 52 9 (0–162) 2 26 (23–28) 50 8 (0–162) 0.235
LR 25 7 (0–162) 1 28 (28) 24 7 (0–162) 0.400
HR 27 59 (0–59) 1 23 (23) 26 10 (0–59) 0.667
Sarcoma
Total 86 43 (1–730) 56 56 (4–454) 30 28 (1–730) 0.001
LR 51 44 (1–365) 33 56 (4–365) 18 28 (1–195) 0.002
HR 35 42 (1–730) 23 56 (5–454) 12 31 (1–730) 0.132
Total 592 21 (0–2034) 249 28 (0–1260) 343 18 (0–2034) <0.001
ALL, acute lymphoblastic leukemia; LR, low risk; HR, high risk; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CNS, central nervous system; SI, 
symptom interval.
*Symptom interval (days) was expressed as median (range), †p values of Mann-Whitney U tests.
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SI
In all patients, the mean SI was 59.7±142.4 days, and the medi-
an SI was 21 (0–2034) days. SI was different between LR and HR 
[median 28 (0–1260) vs. 21 (0–2034); p=0.026]. The median SI 
was longer in patients with CNS tumors [28 (0–2034) days] and 
sarcomas [43 (1–730) days] than in patients with other diagno-
ses (p<0.001) (Table 2).
The median SI was significantly longer in adolescents [28 (0–
1260) days] than in children [18 (0–2034) days; p<0.001]. Medi-
an SIs were also significantly longer in adolescents with CNS 
tumors [29 (0–1079) days] or sarcomas [56 (4–454) days] than in 
children with CNS tumors [25 (0–2034) days; p=0.007] or sarco-
mas [28 (1–730) days; p=0.001]. SIs significantly differed ac-
cording to diagnosis in both children (p<0.001) and adolescents 
(p<0.001). In both groups, sarcoma patients had the longest SIs 
(Table 2).
SI, PD, and PDP in children and adolescents
Because patients with short SIs had worse OS rates than those 
with long SIs, we determined how PD affected SIs. PD data were 
available for 54.4% of the total cohort. PD was significantly 
longer in adolescents [18 (0–365) days] than in children [7.5 
(0–719) days; p<0.001], as was SI as described above. However, 
PDP was the same in adolescents [0.743 (0–1.0)] and children 
[0.750 (0–1.0); p=0.743].
We next analyzed survival rates according to the PDP. Chil-
dren had similar OS rates regardless of the PDP (<0.6, 67.1± 
5.6%; ≥0.6, 71.2±4.2%; p=0.753), whereas adolescents had worse 
OS rates when the PDP was ≥0.6 (64.0±5.1%) than <0.6 (81.8± 
5.8%; p=0.049). In all patients (total cohort, children and ado-
lescents) with short SIs (<21 days) had similar OS rates regard-
less of the PDP (<0.6, 58.9±6.6%; ≥0.6, 62.8±5.0%; p=0.565). 
However, patients with long SIs (≥21 days) had significantly 
higher OS rates when the PDP was <0.6 (86.2±4.5%) than ≥0.6 
(72.6±4.2%; p=0.023). 
Patients were categorized to short SI (n=261) and long SI 
(n=170), and then patients with long SIs were further catego-
rized as follows: long SI/PDP <0.6 (n=53) and long SI/PDP ≥0.6 
(n=117). We did not stratify the patients with short SIs accord-
ing to PDP because it did not affect their survival. To show the 
effect of PDP in patient with long SI, long PDP group was strati-
fied. The proportion of short SI group in children (n=181, 52.8%) 
was higher than in adolescents (n=80, 32.1%), and the propor-
tion of the long SI/PDP ≥0.6 group (n=65, 26.1%) in adolescents 
was higher than in children (n=52, 15.2%) (p<0.001) (Supple-
mentary Table 1, only online). There was a significant survival 
difference among the three groups in the total cohort: the 5-year 
OS rates in the long SI/PDP <0.6, long SI/PDP ≥0.6, and short 
SI groups were 86.8±4.7%, 73.3±4.1%, and 65.1±2.9%, respec-
tively (p=0.001) (Fig. 2A). In other words, the patients with long 
SI but low PDP showed highest survival rates.
In adolescents, OS rates differed significantly according to 
the SI/PDP category (p=0.026) (Fig. 2B). In pairwise compari-
sons, OS rates were significantly higher in the long SI/PDP <0.6 
group (95.5±4.4%) than in the long SI/PDP ≥0.6 group (67.2±5.9%; 
p=0.007). More patients with CNS and sarcoma were in the 
long SI/PDP ≥0.6 group (p<0.001) and more patients with ALL 
or AML were in the short SI group than patients with other di-
agnoses (p<0.001); this observation applied to both children 
and adolescents (Table 3). Adolescents in the short SI group 
had the highest proportion of late stage (HR) cancers (57/106, 
53.8%), whereas those in the long SI/PDP ≥0.6 group had the 
highest proportion of early stage (LR) cancers (27/61, 44.3%); 
however, the differences were not significant (p=0.105).
In children, OS rates also differed significantly according to 
the SI/PDP category (p=0.023) (Fig. 2C). In pairwise compari-
sons, OS rates were not significantly different in the long SI/
PDP <0.6 (80.6±7.1%) and long SI/PDP ≥0.6 (80.8±5.5%; p= 
0.909). Children in the short SI group had a significantly lower 
OS rate (63.8±5.4%) than other patients in the SI/PDP groups 
(p=0.023) (Fig. 2C). In the long SI/PDP ≥0.6 group, there were 
more children with AMLs, sarcomas, and CNS tumors than with 
other diagnoses (p<0.001) (Table 3). There was no significant 
difference between the proportion of children in the SI/PDP gr-
oup and tumor stage (data not shown, p=0.783).
Multivariate analysis
A multivariate analysis of children and adolescents was per-
formed. Children in the short SI group tended to have higher 
hazard ratio than those in the long SI/PDP <0.6 group [2.142; 
95% confidence interval (CI), 0.891–5.151] (Supplementary 
Table 2, only online). The long SI/PDP ≥0.6 and long SI/PDP 
Fig. 2. Overall survival rate according to the symptom interval (SI) and patient delay proportion (PDP) in all patients (A), adolescents (B), and children 
(C). No data, patients without patient delay information.
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<0.6 groups showed similar hazard ratio (1.079; 95% CI, 0.388–
2.995; p=0.885). High stage was a highly significant indepen-
dent predictor of OS (hazard ratio, 4.655; 95% CI, 2.560–8.465; 
p<0.001) in children.
Adolescents in the long SI/PDP ≥0.6 group tended to have 
higher hazard ratio than those in the long SI/PDP <0.6 group 
(6.483; 95% CI, 0.864–48.651; p=0.069). The short SI group also 
tended to show higher hazard ratio (5.505; 95% CI, 0.730–41.531; 
p=0.098). Patients with AML showed a tendency toward high-
er hazard, compared with patients with ALL (hazard ratio, 2.279; 
95% CI, 0.965–5.383; p=0.060). High stage was significantly as-
sociated with higher hazard ratio (4.282; 95% CI, 1.881–9.744; 
p=0.001) (Table 4).
DISCUSSION
Our study found long SIs to be associated with higher survival 
rates. We compared SIs and PDs in adolescents and children 
with cancer. Adolescents in the long SI/PDP ≥0.6 group had 
worse OS rates than those in the short SI and long SI/PDP <0.6 
groups. Adolescent cancer patients are positioned in a gray area 
between pediatric oncology and adult oncology. In addition, 
lack of awareness about themselves, their community, and 
the healthcare system, the paucity of suitable adolescent pro-
tocols, and their poor accrual in clinical trials all lead to worse 
outcomes, such as cancer progression at diagnosis or reduced 
survival.3,5,8,9,16-18 To improve survival, their characteristics re-
quire further exploration.
Adolescence is a period of physical and neuroendocrinologi-
cal development7,14 that is associated with numerous psycho-
logical changes, including development of autonomy, increased 
affiliation with peers, risk taking, and alcohol and other drug 
use.7,14,19,20 Adolescents may have their health issues less close-
ly monitored by their parents and may be more reluctant to 
disclose symptoms.2,21,22 These factors cause behavioral chang-
es including health-seeking patterns. Whereas the cut-off age 
definition of adolescent and young adult in oncology field is 
15 years old, the adolescent-associated developmental chang-
es (puberty) begin around 9–10 years of age in both sexes.23,24 
These changes and consequent behavioral problems in can-
cer clinics are often encountered by clinicians. Therefore, we 
chose 10 years as the cut-off age for adolescents (as opposed to 
Table 3. Distribution of Symptom Intervals and Patient Delay Proportions According to Diagnosis
Diagnosis Long SI/PDP <0.6 Long SI/PDP ≥0.6 Short SI Total
Children
ALL 4 (4.8%) 13 (15.7%) 66 (79.5%) 83
AML 0 (0%) 5 (38.5%) 8 (61.5%) 13
NHL 9 (32.1%) 3 (10.7%) 16 (57.1%) 28
CNS tumor 15 (18.3%) 21 (25.6%) 46 (56.1%) 82
Abdomen 1 (2.4%) 4 (9.8%) 36 (87.8%) 41
Sarcoma 2 (11.8%) 6 (35.3%) 9 (52.9%) 17
Total 31 (11.7%) 52 (19.7%) 181 (68.6%) 264
Adolescents
ALL 1 (4.0%) 7 (28.0%) 17 (68.0%) 25
AML 0 (0%) 3 (17.6%) 14 (82.4%) 17
NHL 4 (28.6%) 2 (14.3%) 8 (57.1%) 14
CNS tumor 12 (16.4%) 27 (37.0%) 34 (48.6%) 73
Sarcoma 5 (13.2%) 26 (68.4%) 7 (18.4%) 38
Total 22 (13.2%) 65 (38.9%) 80 (47.9%) 167
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CNS, central nervous system; SI, symptom interval; PDP, pa-
tient delay proportion.
Table 4. Multivariate Analysis of Risk Factors Related to Overall Survival 
in Adolescents
Variables Hazard ratio p value 
Sex
M 1
F 1.358 (0.756–2.440) 0.306
Diagnosis
ALL 1
AML 2.279 (0.965–5.383) 0.060
NHL 0.269 (0.034–2.140) 0.214
CNS tumor 0.622 (0.280–1.383) 0.244
Solid tumor 1.628 (0.696–3.807) 0.261
Group
Long SI/PDP <0.6 1
Long SI/PDP ≥0.6 6.483 (0.864–48.651) 0.069
Short SI 5.505 (0.730–41.531) 0.098
Stage
Low 1
High 4.282 (1.881–9.744) 0.001
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-
Hodgkin lymphoma; CNS, central nervous system; SI, symptom interval; PDP, 
patient delay proportion.
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children) in our study.
The SI was longer in adolescents than children. CNS tumors 
and sarcomas were more frequent in adolescents, and these 
tumors are associated with longer SIs,25-27 perhaps owing to 
their vague or nonspecific symptoms.27-29 The SI was shorter 
in patients with NBs and WTs than in patients with other can-
cers, which is consistent with the results of a previous study.30 
NBs and WTs are more frequent in children than in other age 
groups. The SI (or diagnostic delay) is generally dependent on 
the cancer type.31-33 Other factors that can affect it are the first 
contacted healthcare provider, the anatomic site of the tumor, 
and the age of the patient at diagnosis.34 Some reports did not 
observe a relationship between SI and tumor type, perhaps 
because cancer type is a function of diagnostic age and tumor 
site.34 However, only a small percentage of the variance in SIs 
(approximately 20%) can be explained by factors other than 
cancer type.34
Health care systems and geographical differences also af-
fect the SI and PD.22,33,34 Thus, SI data from different countries 
cannot be easily extrapolated from one country to another. In 
smaller countries, the health care systems are more homoge-
neous than in larger countries, and SIs are not generally af-
fected by geographical or system-related issues.22,34 In Korea, 
the health care system is fairly homogeneous. The primary 
physician for children and adolescents is a pediatrician rather 
than a general physician. Because of their familiarity with pe-
diatric cancers, pediatricians can reduce the time between the 
patient’s first visit and diagnosis.35 Therefore, PD rather than 
PhyD is the main determinant of the SI, secondary to tumor 
type in Korea, and the effect of PD on cancer can be more easily 
studied in homogeneous medical systems such as those in Ko-
rea, compared with large countries.34
We found that survival rates were higher in patients with long 
SIs than those with short SIs. Longer SIs are generally thought 
to negatively affect survival, because they may involve more 
advanced stages of cancer. The fact that long SIs had better sur-
vival rates was puzzling. The effect of the SI on survival is con-
troversial and was unresolved in a recent systematic review.31,32 
Patients with fast-growing, aggressive cancers may become 
aware of their symptoms earlier than those with slow-growing 
cancers, resulting in shorter SIs.11,12,33,36 Although most of the 
studies addressing the relationship between SI and survival 
were retrospective and therefore limited,11,31-33 a recent study 
was from the analysis from 2 prospective data.37 This study, 
which included Ewing sarcoma patients enrolled in prospective 
trials in France, did not show an effect of SI on survival. How-
ever, in their response to this study, Alonso, et al.38 note that 
reducing diagnostic delays to improve treatment results is 
possible. Furthermore, there was no PD information in the pro-
spective study in France. Therefore, to evaluate the effect of PD 
on survival and to perhaps explain the paradoxical effect of SI 
on survival, we stratified patients according to SI length. We 
chose a cut-off of 21 days for long versus short SIs, because this 
is the maximum time required for spontaneous resolution of 
an acute illness.39,40 After 21 days, the patient should seek med-
ical help because unresolved symptoms usually indicate sub-
acute to chronic illness.39,40
Because patients in the short SI group had the worst survival 
and the SI and PD could not be shortened further, we analyzed 
the characteristics of patients with long SIs with the aim of im-
proving their survival by reducing SI or PD. The relationship 
between PDP and survival differed between children and ad-
olescents. In children with long SIs, the PDP was unrelated to 
survival, whereas in adolescents with long SIs, a PDP ≥0.6 was 
associated with worse survival. This result indicates that seek-
ing medical help promptly and undergoing comprehensive fol-
low-ups by primary physicians, and thus decreasing the PDP, 
can improve the survival of adolescents, compared with chil-
dren. Moreover, unlike risk factors such as sex, age, stage, and 
cancer type, PDP and PD can be modified by educating pa-
tients and their parents. Medical resources can make patients 
and family members more vigilant for signs of cancer, and con-
sequent early diagnosis can potentially improve survival rates.22
Previous studies have shown that older patients have longer 
PDs.22,31 This finding is consistent with those of our study of ad-
olescents. Because adolescent patients and their parents can-
not always remember when symptoms began and first physi-
cian contact was made (parameters required for the calculation 
of PD), PD cannot be studied easily. The effect of PD on sur-
vival has not been studied well,31,33,41 and the effect of PD in ad-
olescents has not been reported previously.31,33 According to a 
systematic review, breast cancer patients with delays of ≥3 
months have lower survival rates than those with delays <3 
months; however, these patients were not adolescents or chil-
dren.13 Goyal, et al.36 found that SI did not affect survival out-
come but did not analyze the effects of PD or the PDP on sur-
vival or the PD/SI relationship. Dang-Tan, et al.22 reported that 
PD seemed to be prolonged in older patients. Their study was 
conducted to assess diagnostic delays and PDs in patients <20 
years old. It used data from the large registry of the Treatment 
and Outcome Surveillance component of the Canadian Child-
hood Cancer Surveillance and Control Program from 1995 to 
2000 (2896 patients). The studied parameters were similar to 
those in our study. However, there was no information on can-
cer stage, and the effect of diagnostic delay on survival was not 
shown.
To shorten PDs, we provide the following suggestions. Be-
cause adolescents are generally healthy, symptoms are fre-
quently ignored. Adolescents who are aware of their symptoms 
often do not report them to their parents owing to their grow-
ing sense of identity, which is influenced by self-esteem and 
mood.7,10,14 They also may not access the proper medical ser-
vices or clinical trials.7,8,42 This indicates the need for public 
education on the importance of short PDs and routine check-
ups. Careful clinical follow-ups by primary physicians after 
the patient has visited a clinic can facilitate referral to a tertiary 
http://dx.doi.org/10.3349/ymj.2016.57.3.572578
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care center at the proper time. We have to work to boost adoles-
cents’ confidence and increase communication about cancer 
and other health issues.43
A limitation of our study is its retrospective design, which 
may have resulted in selection bias. Because we studied patients 
at only one institution, we did not have a sufficient number of 
patients to determine the PD/SI effect on the survival rates for 
specific diagnoses. PD is an interesting parameter, although 
there were difficulties in collecting relevant data: only 54% of 
the patients in our study were included in the PD analysis. Im-
perfect collection of information is frequent in studies of PD.17,34 
Nevertheless, our study is one of the very few addressing the 
relationship between survival and PD in adolescents. We re-
viewed medical records for information about cancer stage and 
survival rates, and our patients received uniform treatments at 
one institution. This may lessen heterogeneous multi-institu-
tional effects on survival and enable studies of the effects of SIs 
and PDs on survival.
In conclusion, adolescents with a long SI/PDP ≥0.6 had lower 
survival rates than those with a short SI or a long SI/PDP <0.6. 
Adolescents are recommended to seek medical help for symp-
toms and signs of cancer to shorten PDs to improve survival 
outcomes.
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